Project Grant R41CA298020
Award Date
6/9/25
Completion Date
5/31/26
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Immunogenik, Inc. (XGX9CKVE5N68)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $549,962 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct structure-function studies on the immunosuppressive receptor Lymphocyte-Activation Gene 3 (LAG3) and its interactions with antibodies and cellular ligands. The goal is to gain fundamental insights into LAG3 molecular biology, which could enable the development of improved LAG3-targeted cancer...
This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,418,424 to Tigatx Inc., a small business located in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, with a focus on non-small cell lung cancer (NSCLC). The award will fund activities to progress TIGA-001 into clinical testing, including chemistry, manufacturing, and controls...
This federal Project Grant award of $696,569 from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program supports research by New York University (NYU) School of Medicine to develop novel therapeutic strategies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment; 2) develop antibody-based therapies that target LCN2 and assess their efficacy as monotherapy and in combination...
This $676,006 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund research to develop non-invasive imaging strategies to identify mechanisms of resistance to cancer immunotherapy early after treatment. The researchers will utilize PET imaging to measure markers of immune response and neutrophil levels, as well as implantable fluorescence sensors to continuously monitor these parameters in vivo. They will pair these molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California provides $650,450 in funding from July 1, 2025 to June 30, 2030 to develop a novel TCR-engineered CD4+ T cell immunotherapy product for the treatment of lung cancer. The key products and services to be delivered under this award include: 1) Determining the mechanisms by which the MIIC4 TCRM50A-STEM2 T cell product eliminates lung cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
This $546,625 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is focused on developing a novel immunochemotherapy approach for treating metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award (1/9/2025 - 12/31/2029) include: Developing and characterizing a nanocarrier platform (PCL-CP) capable of co-delivering siRNA targeting the IRHOM1 gene and a prodrug conjugate of camptothecin...
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This $754,511 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to identify host genetic factors that influence the response to immune checkpoint inhibitor (ICI) cancer treatments. The principal investigator is using a mouse experimental platform to map quantitative trait loci (QTLs) associated with anti-tumor response to anti-PD1 immunotherapy, with a focus on defining the genetic mechanisms behind epistatic interactions...